Subj: allp
I was alerted to ALLP ,, and Oxygent blod substitute,, to be used temporary ,, 6 - 12 hours as a means to supply the oxygen factor into veins to be used during the critical infusion ,,, by one of our MD member,,
I had checked the story out with another MD member and he was very excited and I include both of their comments here ,,
I discovered this site ,, noblood.com and did some layman's research and found out that Baxter gave up their pursuit on the research and dropped 75 million in losses ,, There also is Northfield Laboratories who are now in phase II , but was told to expand their clinical patient numbers,, in view of this ALLP is now entering phase III ,,
The normal phase III takes several months ,, but at this price of 4 5/8 from the high of 11.95 seems to be a good entry to get into .. as it just broke over 200 DMA , we obviously missed the low of 2 1/2 but it was brief and was there for only 2 days on a low volume,,
I also wrote to the various medical staff including Phds,, who are working on the No Blood ! ,,, here are their responses,,
>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>
From MD A
Joe
I'm an MD. Alliance Pharmaceutical (allp) is entering phase three of FDA
approval on a blood substitute and a liquid to fill the lungs with to
provide oxygen. Most docs think they will work out. For what its
worth......
>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>
From Me
This is the response I got from my other MD friend,,
We need to know the length of the Phase III ,, current effacy status ,, FDA's comments.. and over all time span,, even though we missed the bottom ,, if ALLP can pull it off ,, we are talking , ,120 dollar open ,, please stay close and feed me alll the info you can so members can frigging retire ,, all of them ..
;-)
<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<
From MD B
Joe,
Now THIS is good stuff!! I've previously heard about their blood substitute Oxygent, but frankly it has been caught lately in the wake of the negative news surrounding Baxter's HemAssist and Northfield Lab's PolyHeme FDA problems and unfairly lumped along with them. This product, along with their Liquivent (a oxygen-carrying liquid that can be infused in the lungs of patients with lung injury) and Imagent (an ultrasound contrast agent) are now entering Phase III trials and are VERY EXCITING prospects. Oxygent may finally be the real thing as far as blood substitutes are concerned and would be an extremely lucrative product if it gains FDA approval.
News of positive prelim results from the Oxygent Phase III trials would hit the market like a sledgehammer (a la ENMD or GERN) with a quick and possibly sustained rise in price. I'm going to look more into the trial status of these products but I think ALLP is a potential winner. Kudos to your MD tipster.
Scott |
